OSE Immunotherapeutics SA (EPA:OSE)
3.050
-0.024 (-0.78%)
Apr 24, 2026, 3:18 PM CET
OSE Immunotherapeutics Revenue
In the year 2025, OSE Immunotherapeutics had annual revenue of 1.78M EUR, down -97.86%. OSE Immunotherapeutics had revenue of 862.00K in the half year ending December 31, 2024, a decrease of -61.77%.
Revenue
1.78M
Revenue Growth
-95.84%
P/S Ratio
38.68
Revenue / Employee
27.84K
Employees
64
Market Cap
68.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.78M | -81.65M | -97.86% |
| Dec 31, 2024 | 83.44M | 81.21M | 3,646.52% |
| Dec 31, 2023 | 2.23M | -16.08M | -87.83% |
| Dec 31, 2022 | 18.30M | -8.00M | -30.43% |
| Dec 31, 2021 | 26.31M | 15.89M | 152.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| genOway Société anonyme | 20.96M |
| Fermentalg | 13.38M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
| MaaT Pharma | 4.52M |
| ABIONYX Pharma | 4.10M |
| Adocia | 3.85M |
OSE Immunotherapeutics News
- 1 day ago - OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting - GlobeNewsWire
- 9 days ago - OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting - GlobeNewsWire
- 9 days ago - OSE Immunotherapeutics Evolves its Leadership Team - GlobeNewsWire
- 4 weeks ago - OSE Immunotherapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - OSE Immunotherapeutics Announces its 2026 Financial Calendar - GlobeNewsWire
- 6 weeks ago - OSE Immunotherapeutics Confirms Marc Le Bozec As CEO To Drive Next Phase Of Growth - Nasdaq
- 7 weeks ago - OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® - GlobeNewsWire
- 3 months ago - OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab - GlobeNewsWire